-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equal-Weight, Maintains Price Target to $767

Benzinga·12/03/2025 15:31:16
語音播報
Morgan Stanley analyst Matthew Harrison downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Overweight to Equal-Weight and maintains the price target from $767 to $767.